# PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF: SI Lobbying

> PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA: $64.5M disclosed on 7 lobbying reports that name SI issues, Q1 2025 to Q3 2026. Free to cite.

Source: https://tsio.si/money-map/pharmaceutical-research-and-manufacturers-of-america/
Updated: 2026-11-19
Publisher: The SI Observatory (tsio.si), run by the SI community, built by Codeflex

1. [Home](https://tsio.si/)
2. [SI Money Map](https://tsio.si/money-map/)
3. PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

SI Money Map · Client

# PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA and SI policy

**PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA is the client on 7 federal lobbying reports that name SI issues, Q1 2025 to Q3 2026, disclosing $64.5M by the amount rule: $37.9M in 2025 and $26.6M in 2026 so far.** It filed 7 reports for itself. Rank 3 of 1,245 clients. Read from LDA.gov, Nov 17, 2026. Amounts are filing totals for all issues on each filing.

Updated **Nov 17, 2026** · Rank **3** · **7** SI filings

The filings

[Every company](https://tsio.si/money-map/#companies)

[Share on X](https://x.com/intent/post?text=PHARMACEUTICAL+RESEARCH+AND+MANUFACTURERS+OF+AMERICA%3A+%2464.5M+disclosed+on+7+lobbying+reports+that+name+SI+issues.+From+LDA.gov%2C+on+the+SI+Money+Map%3A&url=https%3A%2F%2Ftsio.si%2Fmoney-map%2Fpharmaceutical-research-and-manufacturers-of-america%2F)

- **Reported, all quarters**: $64.5M
- **SI filings**: 7
- **Quarters with filings**: 7
- **Lobbyist IDs on SI**: 29

Over time

## Quarter by quarter

Q1 2025 to Q3 2026. Q3 2026 reports were due Oct 20, 2026.

*Chart: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA: reported amount by quarter. By the amount rule: the in-house report when there is one, else the outside firms' reports.*

| Quarter | Filings | In-house | Outside firms | Counted |
|---|---|---|---|---|
| Q3 2026 | 1 | $7,040,000 | none | **$7,040,000** |
| Q2 2026 | 1 | $7,360,000 | none | **$7,360,000** |
| Q1 2026 | 1 | $12,210,000 | none | **$12,210,000** |
| Q4 2025 | 1 | $8,410,000 | none | **$8,410,000** |
| Q3 2025 | 1 | $9,030,000 | none | **$9,030,000** |
| Q2 2025 | 1 | $7,580,000 | none | **$7,580,000** |
| Q1 2025 | 1 | $12,880,000 | none | **$12,880,000** |

SI filings and amounts by quarter. Counted: the in-house amount when PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA filed an SI report for itself that quarter, otherwise the outside firms' amounts. Subcontracts are never added.

The filings

## Every SI filing for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Each LD-2 report with at least one issue line that names SI, newest first, with the link to the filing on LDA.gov. "SI lines" shows how many of the filing's issue lines name SI.

| Quarter | Filed by | Amount | SI lines | Issue codes and bills | Source |
|---|---|---|---|---|---|
| Q3 2026Q3, posted Oct 20, 2026 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAIn-house | $7,040,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1492, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 3521, H.R. 4317 ... | [LDA.gov](https://lda.gov/filings/public/filing/afab4741-599f-4aea-ae8f-597ba4797e76/print/) |
| Q2 2026Q2, posted Jul 20, 2026 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAIn-house | $7,360,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269, H.R. 3521 ... | [LDA.gov](https://lda.gov/filings/public/filing/956076c6-86a3-42ed-bf18-8375d3295b7b/print/) |
| Q1 2026Q1, posted Apr 20, 2026 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAIn-house | $12,210,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269 ... | [LDA.gov](https://lda.gov/filings/public/filing/1418a58b-0775-4e45-9b77-06e8109c2656/print/) |
| Q4 2025Q4, posted Jan 20, 2026 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAIn-house | $8,410,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269 ... | [LDA.gov](https://lda.gov/filings/public/filing/7b3aeb18-d5fc-4d57-8b7f-3fd1543aefaa/print/) |
| Q3 2025Q3, posted Oct 20, 2025 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAIn-house | $9,030,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 2821, H.R. 3152, H.R. 3160 ... | [LDA.gov](https://lda.gov/filings/public/filing/58c76360-7456-4db5-ad64-8e4ed4b734ae/print/) |
| Q2 2025Q2, posted Jul 21, 2025 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAIn-house | $7,580,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1, H.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 3152, H.R. 3160, H.R. 3269 ... | [LDA.gov](https://lda.gov/filings/public/filing/05706bbb-39a8-4a45-91d5-151396fd20a1/print/) |
| Q1 2025Q1, posted Apr 21, 2025 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAIn-house | $12,880,000 | 2 of 5 | Copyright/Patent/Trademark, Health IssuesH.R. 1262, H.R. 1492, H.R. 1574, H.R. 2214, H.R. 890, H.R. 946, S. 1040, S. 1041 ... | [LDA.gov](https://lda.gov/filings/public/filing/75a3fc67-1a86-4825-a3d0-d29f4b8b5fd6/print/) |

Amount: income reported by an outside firm, or expenses reported in-house, for all issues on the filing.

In their own words

## What the filings say

The SI issue lines, quoted as filed: newest first, repeats left out, long lines cut short. The words are the filers'; the filings are public records.

- **Names as filed**: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
- **Issue codes**: Copyright/Patent/Trademark (7), Health Issues (7)
- **Bills named**: S. 2658 (10), H.R. 890 (7), S. 1040 (7), S. 1041 (7), S. 1095 (7), S. 1096 (7), S. 1097 (7), S. 43 (7), H.R. 1492 (7), H.R. 2214 (7), H.R. 946 (7), S. 652 (7)

1. Q3 2026 "S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent ..." Copyright/Patent/Trademark, filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA. [The filing](https://lda.gov/filings/public/filing/afab4741-599f-4aea-ae8f-597ba4797e76/print/)
2. Q3 2026 "S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. ..." Health Issues, filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA. [The filing](https://lda.gov/filings/public/filing/afab4741-599f-4aea-ae8f-597ba4797e76/print/)
3. Q1 2026 "S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and ..." Copyright/Patent/Trademark, filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA. [The filing](https://lda.gov/filings/public/filing/1418a58b-0775-4e45-9b77-06e8109c2656/print/)
4. Q1 2026 "S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - ..." Health Issues, filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA. [The filing](https://lda.gov/filings/public/filing/1418a58b-0775-4e45-9b77-06e8109c2656/print/)
5. Q2 2025 "S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring ..." Health Issues, filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA. [The filing](https://lda.gov/filings/public/filing/05706bbb-39a8-4a45-91d5-151396fd20a1/print/)
6. Q1 2025 "S. 652: Protecting Patients from Deceptive Drug Ads Act S. 705: Innovation in Pediatric Drugs Act of 2025 S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 891: Bipartisan Health Care Act (including section 227 - ..." Health Issues, filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA. [The filing](https://lda.gov/filings/public/filing/75a3fc67-1a86-4825-a3d0-d29f4b8b5fd6/print/)

Embed

## Put this card on any page

A plain image that links back here, with its source printed on it. Free under CC BY 4.0. **Filings, not influence.** The SI Money Map shows what federal disclosure filings report: who paid for lobbying, which issues and bills the filings name, and what super PACs raised and spent. It does not show influence, intent or results, and it takes no side.

Copy the embed

```
<a href="https://tsio.si/money-map/pharmaceutical-research-and-manufacturers-of-america/"><img src="https://tsio.si/money-map/pharmaceutical-research-and-manufacturers-of-america/card.svg" width="480" height="240" alt="The SI Money Map: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA, $64.5M reported on SI lobbying filings"></a>
```

![SI Money Map card for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA](https://tsio.si/money-map/pharmaceutical-research-and-manufacturers-of-america/card.svg)
